AIM

AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen in Metastatic Triple-Negative Breast Cancer

Retrieved on: 
Tuesday, November 14, 2023
CTL, AIM, Safety, NYSE, Senior, Breast cancer, Celecoxib, Roswell Park, Rintatolimod, Paper, Patient, TLR3, Journal, Immunology, CKM, Pembrolizumab, AIM ImmunoTech, Science of team science, Immunotherapy, Doctor of Philosophy, Manuscript, Pharmaceutical industry, Management, Cancer, MD

OCALA, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the publication of results from the Phase 1 study at Roswell Park Comprehensive Cancer Center in patients with metastatic triple-negative breast cancer using chemokine modulation therapy, including AIM ImmunoTech Inc.’s drug candidate Ampligen® (also known as rintatolimod), interferon α-2b and celecoxib, followed by pembrolizumab.

Key Points: 
  • OCALA, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the publication of results from the Phase 1 study at Roswell Park Comprehensive Cancer Center in patients with metastatic triple-negative breast cancer using chemokine modulation therapy, including AIM ImmunoTech Inc.’s drug candidate Ampligen® (also known as rintatolimod), interferon α-2b and celecoxib, followed by pembrolizumab.
  • The data were published in a manuscript titled, “ Systemic Infusion of TLR3-Ligand and IFNα in Breast Cancer Patients Reprograms Local Tumor Microenvironment for Selective CTL Influx ,” in The Journal for ImmunoTherapy of Cancer.
  • The pilot study evaluated the safety of systemic CKM composed of intravenous rintatolimod (Ampligen; selective TLR3 ligand), interferon α-2b and celecoxib, and the combination’s ability to promote local CTL influx to mTNBC lesions.
  • For more information about the study, please visit ClinicalTrials.gov: NCT03599453 .

Q3 2023 Financial Results

Retrieved on: 
Tuesday, November 14, 2023
AIM, A Funk Odyssey, SIA, Environmental impact assessment, Nasdaq Iceland, Anders Stendalen, REE, Workforce, Social impact assessment, Gold, EIA, Financial statement, Mining, ALS, Rehabilitation, Data collection, Metal, EPCM, University, Engineering, Strategy, Platinum, Vein, Rare-earth element, Cryptocurrency, Construction, Uranium mining, Clothing, Self storage, Greenlandic

TORONTO, ONTARIO – 14 November 2023 - Amaroq Minerals Ltd. (AIM, TSXV, NASDAQ Iceland: AMRQ), an independent mine development company with a substantial land package of gold and strategic mineral assets in Southern Greenland, is pleased to present its Q3 2023 Financial Results.

Key Points: 
  • TORONTO, ONTARIO – 14 November 2023 - Amaroq Minerals Ltd. (AIM, TSXV, NASDAQ Iceland: AMRQ), an independent mine development company with a substantial land package of gold and strategic mineral assets in Southern Greenland, is pleased to present its Q3 2023 Financial Results.
  • Gold business working capital of $59 million as of September 30, 2023 ($41 million as at June 30, 2023).
  • Strategic Minerals: Results from the Sava drilling programme and initial results from the Stendalen stratigraphic drilling are expected in Q4 2023 or Q1 2024.
  • The following selected financial data is extracted from the Financial Statements for the three months ended September 30, 2023.

Notice of Third Quarter Results

Retrieved on: 
Tuesday, November 14, 2023
Gold, AIM, Nasdaq Iceland, Rare-earth element

TORONTO, ONTARIO – November 14, 2023 – Amaroq Minerals Ltd. (AIM, TSXV, NASDAQ Iceland: AMRQ), an independent mine development company with a substantial land package of gold and strategic mineral assets in Southern Greenland, will release its Quarterly Results for the three months ended 30 September 2023, today, 14 November 2023, after market open.

Key Points: 
  • TORONTO, ONTARIO – November 14, 2023 – Amaroq Minerals Ltd. (AIM, TSXV, NASDAQ Iceland: AMRQ), an independent mine development company with a substantial land package of gold and strategic mineral assets in Southern Greenland, will release its Quarterly Results for the three months ended 30 September 2023, today, 14 November 2023, after market open.

Amaroq announces strengthening of sustainability approach through partnership with ERM

Retrieved on: 
Monday, November 13, 2023
Gold, AIM, Nasdaq Iceland, ERM, Organization, Heart, Greenlandic

The Company has appointed ERM International Group Limited (“ERM”), one of world’s largest advisory firm focused solely on sustainability, to conduct a strategic review of its approach to sustainability management and performance.

Key Points: 
  • The Company has appointed ERM International Group Limited (“ERM”), one of world’s largest advisory firm focused solely on sustainability, to conduct a strategic review of its approach to sustainability management and performance.
  • ERM partners with clients to operationalise sustainability at pace and scale, through a unique combination of strategic transformation and technical delivery capabilities.
  • “Sustainability is at the heart of Amaroq’s purpose to create a Greenlandic legacy.
  • We are excited to be partnering with ERM to strategically review our sustainability approach and we look forward to working with them to implement our vision to support the energy transition and deliver sustainable development in Greenland.”

AE Industrial Partners Promotes Three Senior Leaders to Managing Partner

Retrieved on: 
Monday, December 18, 2023
Public Policy, Government, Finance, Professional Services, Technology, Homeland Security, Aerospace, Manufacturing, Security, AIM, Southern Waste Management Partnership, Aviation, Columbia Helicopters, Economics, AEI, MRO, CDI, Partner (business rank), University, Atlas Group, Investment, History, Alpine Air Express, Davidson College, Engineering, Atlas, Firefly Aerospace, Airline, Pension fund, Belcan

AE Industrial Partners, LP (“AEI”), a private equity firm specializing in aerospace, national security, and industrial services, today announced the promotion of Charlie Compton, Kirk Konert and Jon Nemo to Managing Partner.

Key Points: 
  • AE Industrial Partners, LP (“AEI”), a private equity firm specializing in aerospace, national security, and industrial services, today announced the promotion of Charlie Compton, Kirk Konert and Jon Nemo to Managing Partner.
  • The appointments, which are effective immediately, expand the Managing Partnership to five members.
  • “As our organization continues to evolve, we believe strongly in building from within, and these promotions underscore that commitment.
  • Charlie Compton, who joined AEI in 2014, primarily focuses on commercial aerospace, business aviation and industrial services investments.

Ankyra Therapeutics Announces Pre-Clinical Research Published in December JCI Insight Demonstrating Potent Anti-Tumor Activity of Anchored IL-12 in Multiple Murine Cancer Models

Retrieved on: 
Tuesday, December 12, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Data, IL-12, JCI, Aluminium, AIM, Immunotherapy, Neoplasm, Trial of the century, Journal, Therapy, Cancer, Human, Pharmaceutical industry

Ankyra Therapeutics, an emerging clinical-stage biotechnology company pioneering anchored immunotherapies to treat cancer, today announced results from a preclinical study demonstrating potent anti-tumor activity of its lead program ANK-101 were published in the December issue of the Journal of Clinical Investigation Insight (JCI Insight).

Key Points: 
  • Ankyra Therapeutics, an emerging clinical-stage biotechnology company pioneering anchored immunotherapies to treat cancer, today announced results from a preclinical study demonstrating potent anti-tumor activity of its lead program ANK-101 were published in the December issue of the Journal of Clinical Investigation Insight (JCI Insight).
  • The research paper is titled “Intratumoral aluminum hydroxide-anchored IL-12 drives potent antitumor activity by remodeling the tumor microenvironment.”
    ANK-101 is a novel tumor-directed anchored immune medicine (AIM) composed of interleukin-12 (IL-12) linked to aluminum hydroxide.
  • “Our pre-clinical data indicates that anchored immunotherapy retains active IL-12 at the tumor site for weeks, versus just hours with unanchored recombinant IL-12.
  • This results in potent immune activation with limited systemic exposure, indicating the potential to improve patient outcomes while reducing side effects.

Advanced Bionics Extends Marvel CI Product Offering With Remote Programming and Expanded Linked Two-ear Solutions

Retrieved on: 
Monday, December 4, 2023
FDA, Health Technology, Other Health, Technology, General Health, Medical Devices, Hospitals, Neurology, Science, Biotechnology, Software, Other Science, Health, Mobile, Wireless, Research, Speech, Remote support, Marvel, Ear, AIM, Bionics, Life, Soundwave, Comparison, GVP, Smartphone, AB, Patient, Multimedia, Workflow, Kool-Aid, Sonova, Hearing loss, Deafness, Hearing, Sequence, Travel, Restaurant, Medical device, Fine chemical

Remote Programming is another step towards improving accessibility for hearing healthcare for as many people as possible.

Key Points: 
  • Remote Programming is another step towards improving accessibility for hearing healthcare for as many people as possible.
  • Now AB’s Marvel will also be the only CI system with a CROS (Contralateral Routing of Signal) device.
  • Together with a pair of Marvel CI sound processors, or a bimodal pairing with Marvel CI and a Phonak Link M hearing aid, the introduction of CROS makes Marvel the only CI system with linked bilateral, bimodal, and CROS configurations.
  • “Since its introduction in 2020, Marvel CI has redefined hearing performance with cochlear implants," said Victoria E.Carr-Brendel, Ph.D., GVP, Sonova Group and President of Advanced Bionics.

AIM ImmunoTech Provides Update Regarding Annual Meeting

Retrieved on: 
Tuesday, November 28, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, AIM, NYSE, Annual general meeting, Activism, Notice, Broker, Delaware Court of Chancery, Trustee, Delaware Court, Security (finance), Shareholder

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Company will convene its upcoming 2023 Annual Meeting of Stockholders (the “2023 Annual Meeting”) as planned on December 1, 2023, and will then adjourn proceedings, without conducting any other business, until December 29, 2023.

Key Points: 
  • AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Company will convene its upcoming 2023 Annual Meeting of Stockholders (the “2023 Annual Meeting”) as planned on December 1, 2023, and will then adjourn proceedings, without conducting any other business, until December 29, 2023.
  • As a reminder, the AIM Board unanimously determined that the Activist Group’s nomination notice (the “Notice”) is invalid because it omits key information and includes misleading information, ignoring what the Company’s Bylaws require to be disclosed.
  • The record date for determining shareholders eligible to vote at the 2023 Annual Meeting will remain the close of business on October 2, 2023.
  • If you have any questions or require any assistance in voting your shares, please contact our proxy solicitor:
    Banks, Brokers, Trustees, and Other Nominees Call Collect: (203) 658-9400

USEReady Recognized as a Leader in Generative AI by AIM Research

Retrieved on: 
Monday, November 27, 2023
Data Analytics, Professional Services, Technology, Artificial Intelligence, Software, AIM, Intelligent enterprise, Pocs, Investment, Decision, Research, Pema, Private, AI, Responsibility, Pixel Perfect, Human, Medical device

USEReady , a data analytics solutions provider, has been named a “Leader” in AIM Research's PeMA Quadrant 2023 for Top Generative AI Service Providers.

Key Points: 
  • USEReady , a data analytics solutions provider, has been named a “Leader” in AIM Research's PeMA Quadrant 2023 for Top Generative AI Service Providers.
  • AIM Research specifically cited USEReady's proven track record of converting POCs into long-term partnerships as a key strength.
  • "We are thrilled to be recognized as a Leader in generative AI," said Uday Hegde, Co-founder & CEO, USEReady.
  • AIM Research’s PeMa Quadrant Top Generative AI Service Providers 2023 full report can be accessed here: https://www.useready.com/press-release/useready-recognized-as-leader-in-...

New Relic Launches Industry’s First APM for AI

Retrieved on: 
Tuesday, November 14, 2023
Engineering, Data Management, Technology, Manufacturing, Software, Artificial Intelligence, AIM, LLM, Generative, Organization, Hope, Toxicity, Synthetic media, Hallucination, Quickstart guide, Ecosystem, Comparison, Conifer cone, Bias, AI, Telemetry, APM, Medical device, New Relic

New Relic , the all-in-one observability platform for every engineer, launched New Relic AI monitoring (AIM) , the industry’s first APM solution for AI-powered applications.

Key Points: 
  • New Relic , the all-in-one observability platform for every engineer, launched New Relic AI monitoring (AIM) , the industry’s first APM solution for AI-powered applications.
  • New Relic is pioneering AI observability with AIM to provide engineers unprecedented visibility and insights across the AI application stack, making it easier to troubleshoot and optimize their AI applications for performance, quality, cost, and responsible use of AI.
  • Full AI stack visibility: Holistic view across the application, infrastructure, and the AI layer, including AI metrics like response quality and tokens alongside APM golden signals.
  • “We have seen incredible demand for vector databases as companies build and deploy AI applications since it is a core part of the AI stack.